Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...
Daily16h
Merck WELIREG gets USFDA priority for Advanced Pheochromocytoma and Paraganglioma
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...
Merck announces $0.81 dividend and $10 billion buyback
Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...
Pharmabiz17h
US FDA grants priority review status to Merck’s sNDA for Welireg to treat patients with advanced pheochromocytoma and paraganglioma
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
pharmaphorum22h
Merck turns to cardiovascular pipeline for its post-Keytruda future
Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...